Novocure Ltd
NASDAQ:NVCR
Intrinsic Value
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. [ Read More ]
The intrinsic value of one NVCR stock under the Base Case scenario is 22.24 USD. Compared to the current market price of 12.03 USD, Novocure Ltd is Undervalued by 46%.
Valuation Backtest
Novocure Ltd
Run backtest to discover the historical profit from buying and selling NVCR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Novocure Ltd
Current Assets | 1B |
Cash & Short-Term Investments | 910.6m |
Receivables | 83.9m |
Other Current Assets | 39.9m |
Non-Current Assets | 111.7m |
PP&E | 97.7m |
Other Non-Current Assets | 14m |
Current Liabilities | 179.1m |
Accounts Payable | 94.4m |
Other Current Liabilities | 84.7m |
Non-Current Liabilities | 604.5m |
Long-Term Debt | 568.8m |
Other Non-Current Liabilities | 35.7m |
Earnings Waterfall
Novocure Ltd
Revenue
|
509.3m
USD
|
Cost of Revenue
|
-128.3m
USD
|
Gross Profit
|
381.1m
USD
|
Operating Expenses
|
-613.9m
USD
|
Operating Income
|
-232.9m
USD
|
Other Expenses
|
25.8m
USD
|
Net Income
|
-207m
USD
|
Free Cash Flow Analysis
Novocure Ltd
NVCR Profitability Score
Profitability Due Diligence
Novocure Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Novocure Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
NVCR Solvency Score
Solvency Due Diligence
Novocure Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Novocure Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVCR Price Targets Summary
Novocure Ltd
According to Wall Street analysts, the average 1-year price target for NVCR is 27.88 USD with a low forecast of 15.15 USD and a high forecast of 44.1 USD.
Ownership
NVCR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NVCR Price
Novocure Ltd
Average Annual Return | 28.74% |
Standard Deviation of Annual Returns | 74.21% |
Max Drawdown | -95% |
Market Capitalization | 1.3B USD |
Shares Outstanding | 107 093 000 |
Percentage of Shares Shorted | 6.51% |
NVCR News
Last Important Events
Novocure Ltd
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Novocure Ltd
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Contact
IPO
Employees
Officers
The intrinsic value of one NVCR stock under the Base Case scenario is 22.24 USD.
Compared to the current market price of 12.03 USD, Novocure Ltd is Undervalued by 46%.